232 related articles for article (PubMed ID: 12189541)
1. The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).
Waters JS; O'Brien ME
Br J Cancer; 2002 Aug; 87(5):481-90. PubMed ID: 12189541
[TBL] [Abstract][Full Text] [Related]
2. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
3. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
[TBL] [Abstract][Full Text] [Related]
5. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
Bunn PA; Kelly K
Clin Cancer Res; 1998 May; 4(5):1087-100. PubMed ID: 9607565
[TBL] [Abstract][Full Text] [Related]
6. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
[TBL] [Abstract][Full Text] [Related]
8. [Maintenance chemotherapy in advanced NSCLC].
Krazkowski M
Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S16-8. PubMed ID: 16719150
[No Abstract] [Full Text] [Related]
9. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
[TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy for elderly patients with lung cancer].
Okamoto H; Watanabe K
Nihon Rinsho; 2002 May; 60 Suppl 5():591-5. PubMed ID: 12101743
[No Abstract] [Full Text] [Related]
11. Rationale for non-platinum chemotherapy in advanced NSCLC.
Murren JR
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229
[TBL] [Abstract][Full Text] [Related]
12. [Platinum-free gemcitabine-based combinations: an alternative to conventional chemotherapy of non-small-cell lung cancers?].
Pujol JL; Choma D; Jacot W; Quantin X
Bull Cancer; 2002 Aug; 89 Spec No():S85-90. PubMed ID: 12449036
[TBL] [Abstract][Full Text] [Related]
13. Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
Georgoulias V; Scagliotti G; Miller V; Eckardt J; Douillard JY; Manegold C
Semin Oncol; 2001 Feb; 28(1 Suppl 2):15-21. PubMed ID: 11284620
[TBL] [Abstract][Full Text] [Related]
14. Development of docetaxel in advanced non-small-cell lung cancer.
Belani CP; Eckardt J
Lung Cancer; 2004 Dec; 46 Suppl 2():S3-11. PubMed ID: 15698529
[TBL] [Abstract][Full Text] [Related]
15. [New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
Mavroudis D
Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S42-5. PubMed ID: 11924243
[No Abstract] [Full Text] [Related]
16. Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
Simon GR; Bunn PA
Cancer Invest; 2003; 21(1):87-104. PubMed ID: 12643013
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer.
Belani CP;
Semin Oncol; 2002 Jun; 29(3 Suppl 12):4-9. PubMed ID: 12170445
[TBL] [Abstract][Full Text] [Related]
18. [Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
Morere JF
Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S37-41. PubMed ID: 11924242
[No Abstract] [Full Text] [Related]
19. Chemoradiation in locally advanced non-small cell lung cancer.
Bonomi P; Shirazi W
Cancer Treat Res; 2001; 105():171-88. PubMed ID: 11224987
[No Abstract] [Full Text] [Related]
20. [Concomitant radiochemotherapy for non-small-cell lung cancer: towards an ideal strategy].
Rixe O
Rev Mal Respir; 2001 Sep; 18(4 Pt 1):365-6. PubMed ID: 11547240
[No Abstract] [Full Text] [Related]
[Next] [New Search]
